OTCM
AGYTF
Market cap440mUSD
Jul 02, Last price
0.15USD
Name
Allergy Therapeutics PLC
Chart & performance
P/E
—
P/S
12.90
EPS
—
Div yield, %
—
Shrs. gr., 5y
47.90%
Rev. gr., 5y
-6.78%
Revenues
55m
-0.28%
Net income
-40m
L-0.21%
CFO
-29m
L-10.64%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Allergy Therapeutics plc is a biotechnology firm dedicated to the research and development of innovative treatments for allergies. The company offers a range of injectable and sublingual immunotherapies specifically targeting allergens, alongside diagnostic tools and prescription solutions for pollen-related allergies, including those caused by grasses, weeds, and trees. Its diverse product portfolio features Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. Furthermore, Allergy Therapeutics is actively advancing new vaccine candidates designed to address sensitivities to trees, grass, house dust mites, animal dander, and peanuts. With operations spanning Central Europe, Southern Europe, the United Kingdom, and various other international markets, Allergy Therapeutics plc was established in 2004 and is headquartered in Worthing, UK.
Key people
Peter Sinclair Jensen
Non-Executive Chairman of the Board · since 2011
Nicolas Alexander Ulrich Wykeman
Finance Director · since 2016
Manuel Llobet
Chief Executive Officer, Executive Director · since 2009
Mary Tavener
Non-Executive Director · since 2019
Scott Leinenweber
Non-Executive Independent Director · since 2018
Stephen Rushworth Smith
Senior Non-Executive Independent Director · since 2004
IPO date
Oct 11, 2004
Employees
622
Domiciled in
GB
Incorporated in
GB
Headquarters & legal address
DOMINION WAY
WORTHING, WSX BN14 8SA
GB
WORTHING, WSX BN14 8SA
GB
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||